CSAAI 2017 A Midsummer Night's Wheeze
This program will bring the participant up-to-date on the latest research on preventing allergic illnesses through modification of the microbiome, to use of allergens to modify the immune system (SCIT/SLIT/OIT) to biologics, as well as understand through review and update the immune dysregulation leading to primary immunodeficiencies.
Practicing allergists, primary care physicians and allied healthcare providers in the field of allergy and immunology.
At the conclusion of this activity, participants should be able to:
- Summarize recent advances in understanding how the respiratory microbiome influences asthma and COPD and the factors that influence the respiratory microbiome
- Describe the interactions between therapeutics and the respiratory microbiome and this effect on treatment outcome
- Describe recent advances in understanding how the skin microbiome influences eczema and other allergic skin diseases
- Describe recent treatment modalities for eczema and particularly severe eczema and the effect of modulation of the microbiome
- Describe the effect of air pollutants on the immune system and the impact on asthma and respiratory allergy
- Diagnose and manage exercise anaphylaxis and asthma
- Summarize the recent advances in knowledge of how exposure to oral allergens change the immune system toward tolerance and desensitization and describe the current recommendations and controversial issues
- Summarize recent advances in biologics in the treatment of asthma, including indications and contraindications, modulation of the immune system (cytokine/pathophysiologic changes) with administration, and relevant biologics in the US healthcare market
- Summarize recent advances in biologics in the treatment of allergic skin diseases, including indications and contraindications, modulation of the immune system (cytokine/pathophysiologic changes) with administration, and relevant biologics in the US healthcare market
- Describe recent advances in newly described primary immunodeficiencies (many presenting with CVID-like clinical pictures plus autoimmunity and others with more autoimmunity), and new targeted therapies in the treatment/potential treatment of these diseases
- Describe basic testing for primary immunodeficiencies, as well as describe the recent advances in testing and genomic testing
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.25AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent education grants from CSL Behring, Greer, Sanofi
- 10.25 AMA PRA Category 1 Credit™
- 10.25 Attendance